Liquidity & Technical

Liquidity and Technical

The price record staged for this run covers only the 66 trading days from 2026‑03‑18 through 2026‑06‑18 — too short to compute a 200‑day moving average, a 52‑week range, golden/death‑cross dates, or a multi-year relative-strength series. The page leans on what is in the data (a 66‑day OHLCV record that brackets the April 22 guidance shock and the eight‑week recovery) and pulls capital-structure context from the FY2025 10‑K and Q1 FY2026 transcript. Where the playbook expects a 200‑day or 52‑week answer, the page says so rather than fabricating one.

Liquidity is not the bottleneck — MOH is a roughly $10B mid‑cap with about $189M of value‑weighted 20‑day ADV and a clean single-class capital structure with no promoter or government block. The technical setup is neutral with an upside bias — the post‑shock rebound has reclaimed pre‑disappointment levels, a clear ceiling has built at $204‑205, and the multi-year relative-strength baseline is poor. Implementation read: build into and below the $172 line where the buyback has been active, don't chase $200.

Headline read

Market cap above uses the 51.5 million shares of Common Stock outstanding as of February 6, 2026 [1] disclosed on the cover of the FY2025 10‑K, multiplied by the latest staged close. The 51.5M figure is the foundation for every per‑share, capacity and float number on this page.

Implementation verdict — liquidity is deep, structurally clean

liquidity.json was stamped no_public_market because the upstream pipeline gates the precomputed capacity numbers on a multi-year window MOH's staged file does not have. That gate is a data-pipeline rule, not a market reality: MOH trades on NYSE under the symbol "MOH" [2], is a large accelerated filer [1], and was an S&P 500 constituent benchmark name in the FY2025 stock-performance comparison [2]. Recomputing capacity from the staged OHLCV against the disclosed share count gives the answers below.

At a 20% participation rate over five trading days, a fund can move roughly $189M, or about 968k shares. That clears a 5% position for a fund up to ~$3.8B AUM, a 2% position up to ~$9.4B AUM, and a 10% position up to ~$1.9B AUM. Exiting a 1%‑of‑market‑cap holding (~515k shares) at the same 20%/5d participation takes about 2.7 trading days — the name is institutionally tradable, but a sub‑$4B AUM fund is the comfortable size for an overweight; mega-cap funds will be size‑constrained and have to step their builds.

Execution friction is elevated: the median daily high‑low range over the 66 days is 3.7%, materially wider than the sub‑2% regime a managed-care name normally trades in. Most of that wide range is concentrated around the April shock, but the recovery legs themselves carry 2‑3% daily ranges. The practical read: paper any limit order with care, and assume single‑day impact cost is not the bottleneck — the bottleneck is the regime of vol you are entering, not the size of the line you want to build.

Float quality reinforces, rather than undercuts, the raw‑ADV verdict. MOH has a single class of common stock, par value $0.001 per share [1], no promoter, family or government block, and pays no dividend [2]. The aggregate market value of common stock held by non‑affiliates on the last business day of Q2 2025 was approximately $16.0 billion [1] — the public float is essentially the share count. 13G filers concentrate the register (BlackRock approximately 11.7%, Capital World about 6.8%, Fidelity about 5.8%, AQR about 5.5%, Vanguard family low‑5%, collectively about a third of shares) [9], but these are passive and quant rather than control holders, and they sit in the same flows that make the tape liquid.

The structural buyback is the other liquidity backstop. The board authorized up to $1 billion of common-stock purchases in April 2025, running through December 31, 2026 [3]. As of February 10, 2026, $500 million of the authorization remained [3]. The company has prosecuted these programs in size: it bought approximately 1,679,000 shares for $500 million in Q1 2025 at $297.83, and approximately 2,849,000 shares for $500 million in Q3 2025 at $175.50 [4] — a meaningful indicator of management's willingness to step into weakness. The $500M still on the shelf is roughly 2.5M shares at current levels — about 5% of the float and about 13 days of 20%‑participation ADV — a structurally meaningful bid that will lean against any retest of the lower band.

The April 22 shock is the central feature of the tape

The defining event in the staged record is 2026‑04‑22: the Q1 FY2026 earnings release, in which management reaffirmed — rather than raised — full‑year 2026 guidance of approximately $42 billion of premium revenue and at least $5 of adjusted EPS [5] despite Q1 adjusted EPS of $2.35 on $10.2B of premium revenue, with management explicitly framing the choice as "merely reaffirming our prior full year guidance is a prudent approach at this early point in the year" [6]. The 8‑K filed the same day formally reaffirmed "the Company's full-year 2026 premium revenue and adjusted earnings guidance" [7]. The stock had closed at $171.95 the prior session, opened at $121.06, traded to $137.96 intraday and closed at $133.94 — a one-day decline of 22.1% from prior close, an opening gap of -29.6%, and an intraday range of 14.0%, on volume of 11.18 million shares — approximately 7.9× the average of the rest of the staged record.

What followed the gap is the rest of the story: the stock probed a low of $129.41 on April 27, found a base, then rebuilt for eight weeks back to $194.76, a 45.4% gain from the 4/22 close and a recovery to within 4.6% of the pre-shock period peak. The recovery has the shape of a normal post‑shock V — heavy volume in the first ten sessions (multiple 2.0‑3.1M share days), then declining volume into the climb back to $200. The unfinished business sits at $204‑205: prints of $204.95 on 6/9, $204.45 on 6/10, $204.66 on 6/16 have each been rejected, defining the ceiling.

The April 22 event sits inside a broader narrative the corpus already names. A putative securities class action, Hindlemann v. Molina Healthcare, Inc. et al., was filed on October 3, 2025 in the U.S. District Court for the Central District of California, on behalf of a class who allegedly acquired MOH securities between February 5, 2025 and July 23, 2025 and asserting violations of federal securities laws relating to the Company's disclosures, "including those involving earnings guidance" [8]. A related shareholder derivative action, Taylor v. Wolf, et al., was filed December 12, 2025 [8]. The litigation overhang and a second consecutive guidance disappointment in April 2026 explain why the recovery is unfinished and why the $204‑205 ceiling is so well defended — the market is rationally pricing the option that "at least $5" is still soft.

Trend, regime and momentum

The 200‑day SMA and 52‑week levels are unavailable — the 66‑day window does not span enough history. The short‑MA picture is usable:

The current close of $194.76 sits essentially on the 20‑day SMA ($194.81) and ~11.3% above the 50‑day SMA ($175.06). SMA20 above SMA50, and the gap widening over the past three weeks, is the textbook signature of a recovering uptrend. Without a 200‑day reference, the trend classification stops there: uptrend on the visible window, regime unknown beyond it. The corpus, however, is unambiguous about the longer-period regime: the five‑year cumulative total‑return graph in the FY2025 10‑K shows $100 invested in MOH on December 31, 2020 ended December 31, 2025 worth $80, while the same investment in the S&P 500 ended at $195 and the peer group at $160 [2]. The visible 2026 rebound is happening from a multi‑year relative low, not a multi-year high — which is what makes the technical and the fundamental tabs disagreeable rather than redundant.

RSI(14) closed at 55.8 — the textbook neutral zone. There is no overbought signal that warrants trimming a fresh entry, and no oversold tell that argues for an aggressive add. MACD on a 66‑day window is computable but the histogram is dominated by the gap-day discontinuity and is not informative — skip it on this data.

The action since June 8 has repeatedly tested and failed at $204‑205 — the same prints that capped the pre-shock March 31 peak. A close above $205 reopens the path; a close below the 50‑day at $175 forfeits the recovery's slope; a close below the $172 pre‑shock support says the recovery has failed.

Volume, volatility, sponsorship

Volume confirms the event, less so the recovery's last leg. Of the top five volume days in the 66‑day window, all five fall in the 4/22 → 5/01 window — the panic and the immediate flush. Volume on the climb from $170 to $200 over the last three weeks is conspicuously modest: many sub‑1M share days (964k on 6/1, 867k on 6/2, 724k on 6/3, 884k on 6/4, 665k on 6/5, 879k on 6/15, 711k on 6/16, 867k on 6/17, 300k on 6/18). Below‑average volume on the up‑move is not a refutation of the trend, but it is not the kind of confirming sponsorship a clean breakout would carry — which is consistent with the repeated rejections at $205.

Realized volatility is 34.7% annualized on a 30‑day window — elevated for a managed-care name (typical 20‑30%). On a 60‑day basis it lifts to ~67% because the 4/22 single‑day return mathematically dominates the window; that number will normalize as the gap day rolls off. The honest takeaway: vol regime is elevated and normalizing, not low — risk-budget the position accordingly.

Volume around the structural buyback matters: the $500M still on the shelf through Dec 31, 2026 [3] is about 13 days of 20%‑participation ADV — the program can be a meaningful bid into weakness without straining the tape, and the precedent of executing $500M tranches inside a single quarter (Q1 2025 and Q3 2025, the latter at $175.50 average cost — essentially today's 50‑day SMA) [4] suggests management is willing to step in around this level.

Cross‑reference with the fundamental story

The companion Financials/Quant tab is not yet present in this run, so the cross‑read is one‑directional: the tape and the disclosures broadly agree that the 2025 sell‑off was deserved (a $80/$195 endpoint on the five‑year cumulative chart is not a chart that gets there by accident), and the tape has begun to disagree with the disclosures as it claws back through the post‑shock recovery — pricing some optionality that "at least $5" is conservative even after April 22. The unresolved litigation over the Feb 5 → July 23, 2025 disclosure window [8] is the reason this disagreement does not yet read as conviction.

Technical scorecard

The standard six dimensions, scored against the visible window. Where the playbook expects a 52‑week or 200‑day reference, the score is 0 by force of missing data, not because the picture is neutral.

Sum is −1: the active recovery (Trend +1) is offset by elevated vol and the multi-year relative-strength baseline. Note the multi-year leg of the scorecard is sourced from the 10‑K's own five‑year cumulative-return disclosure [2] — the staged price file alone could not support it.

Stance — 3-to-6 month horizon

Neutral with upside bias. The recovery is real and the structural buyback gives the long side a measurable backstop, but the $204‑205 ceiling has held four times in two weeks, the multi-year relative baseline is dismal, and the second guidance disappointment in twelve months keeps the litigation overhang [8] live. The implementation answer is act, but earn the position: liquidity is not the constraint — a clean 5% position is implementable for funds up to ~$3B AUM at 20%/5d participation. Build a half‑weight into and below the 50‑day at $175 (where the company itself has shown a willingness to repurchase), and let one of the two named levels below decide the rest.

Caveats and what the data does not say

The staged window cannot answer three questions a normal technical page would:

52‑week levels and 200‑day MA — both require ≥252 trading days; the staged record has 66.

Golden‑ or death‑cross dates — both require continuous SMA50 and SMA200 series across a year or more; not computable here.

Multi-year relative strength vs S&P 500 / XLV / peer basket — the staged relative_performance.json is unavailable. The five‑year cumulative‑return numbers used above ($80 / $195 / $160) come from the FY2025 10‑K's stock-performance graph [2] and are anchored to year-end prints, not daily series.

Anything the page does not name above is either uncited because it is a computed price metric from the 66-day staged file, or absent because the data does not support the claim.

References

1. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Cover (shares outstanding, non-affiliate market value, filer status) — p.2
2. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 5: Stock Performance Graph / Trading Symbol / Dividends — p.76
3. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), MD&A — Future Uses: Common Stock Purchases (remaining authorization) — p.92
4. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Note 13 Stockholders' Equity — Stock Purchase Programs (executed buybacks) — p.135
5. Molina Healthcare, Inc. — Q1 FY2026 Earnings Call Transcript (April 23, 2026) — CEO remarks on 2026 reaffirmed guidance — p.1
6. Molina Healthcare, Inc. — Q1 FY2026 Earnings Call Transcript — CEO on "prudent" reaffirmation — p.2
7. Molina Healthcare, Inc. — Form 8-K dated 2026-04-22, Item 2.02 Results of Operations and Financial Condition — p.3
8. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Note 15 Commitments and Contingencies — Hindlemann securities class action / Taylor derivative action — p.139
9. Molina Healthcare, Inc. — Ownership by Owner aggregate (SEC EDGAR SC 13G / 13D filings) — p.1